{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:28:41Z","timestamp":1794965321253,"version":"4.9.1"},"reference-count":126,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriasis is a T cell\u2013mediated disease with autoimmune characteristics modulated by genetic susceptibility along with environmental triggers. Inflammatory pathways marked with excessive production of cytokines IL\u201012 and IL\u201023, drive differentiation of pathogenic T cell responses resulting in TNF and IL\u201017 production. These cytokines are an integral part of the TNF\/IL\u201023\/IL\u201017 axis, which is responsible for maintaining inflammation in psoriatic skin. Our improved understanding of the immunopathogenesis led to the development of biological drugs in the treatment of moderate\u2010to\u2010severe disease. Biologics have revolutionized the management of psoriasis, highlighting the central role of TNF\/IL\u201023\/IL\u201017 axis in the physiopathology of the disease. Still, psoriasis usually requires long\u2010term treatment, aiming to fully remove psoriatic lesions without experiencing adverse events. In this review, we discuss the recent findings of all 27 available head\u2010to\u2010head trials investigating the efficacy and safety of systemic and biologic therapies in moderate\u2010to\u2010severe psoriasis vulgaris, as it is thought to provide more useful knowledge than placebo intervention alone. According to our evaluation, inhibitors that specifically target IL\u201023 or IL\u201017 are clinically more beneficial than inhibitors of IL\u201012\/IL\u201023 and TNF. More informative results might be obtained by comparing these more efficient biological agents to each other. In addition, newer therapies for psoriasis using small\u2010molecule drugs may represent important advances compared to well\u2010established biologics as these are less expensive and orally administered.<\/jats:p>","DOI":"10.1111\/sji.12946","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T10:56:40Z","timestamp":1595415400000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["The TNF\/IL\u201023\/IL\u201017 axis\u2014Head\u2010to\u2010head trials comparing different biologics in psoriasis treatment"],"prefix":"10.1111","volume":"92","author":[{"given":"Lisa Lynn","family":"ten Bergen","sequence":"first","affiliation":[{"name":"Broegelmann Research Laboratory Department of Clinical Science University of Bergen Bergen Norway"},{"name":"Vrije Universiteit Amsterdam Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Petrovic","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory Department of Clinical Science University of Bergen Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Krogh Aarebrot","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory Department of Clinical Science University of Bergen Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2199-2315","authenticated-orcid":false,"given":"Silke","family":"Appel","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory Department of Clinical Science University of Bergen Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"issue":"2","key":"e_1_2_8_2_1","first-page":"ii18","article-title":"Epidemiology, clinical features, and quality of life","volume":"64","author":"Langley RGB","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"e_1_2_8_3_1","first-page":"18","article-title":"Prevalence of psoriasis and psoriatic arthritis and patient perceptions of severity in Sweden, Norway and Denmark: Results from the nordic patient survey of psoriasis and psoriatic arthritis","volume":"99","author":"Danielsen K","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"113","author":"Parisi R","year":"2013","journal-title":"J Invest Dermatol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.12.001"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.693"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02310.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12355"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107263450403"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12845"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16269"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.11.005"},{"issue":"1","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000330330","article-title":"Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: Modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response","volume":"233","author":"Quaglino P","year":"2011","journal-title":"Dermatology"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12725"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202424"},{"key":"e_1_2_8_20_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"1","author":"Sbidian E","year":"2020","journal-title":"Cochrane database Syst Rev"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"e12846","DOI":"10.1111\/sji.12846","article-title":"The CCL20 and CCR6 axis in psoriasis","author":"Furue K","year":"2020","journal-title":"Scand J Immunol"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0738-081X(95)93817-8"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6729.908"},{"issue":"22","key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.1986.03380220076026","article-title":"Cyclosporine improves psoriasis in a double\u2010blind study","volume":"256","author":"Ellis CN","year":"1986","journal-title":"JAMA J Am Med Assoc"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-195102000-00009"},{"issue":"20","key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1073\/pnas.91.20.9282","article-title":"CD8+ T cells in psoriatic lesions preferentially use T\u2010cell receptor V(\u03b2)3 and\/or V(\u03b2)13.1 genes","volume":"91","author":"Chang JCC","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.038"},{"issue":"1","key":"e_1_2_8_28_1","first-page":"1","article-title":"Large scale meta\u2010analysis characterizes genetic architecture for common psoriasis associated variants","volume":"8","author":"Tsoi LC","year":"2017","journal-title":"Nat Commun"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.313"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.311"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.694"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4733"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12812"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"issue":"13","key":"e_1_2_8_36_1","first-page":"133182","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba LC","year":"2007","journal-title":"J Exp Med"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2014.09.002"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.416"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400513111"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2156"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.340"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902464"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.234"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006245"},{"issue":"204","key":"e_1_2_8_45_1","article-title":"IL\u201026, a cytokine with roles in extracellular DNA\u2010induced inflammation and microbial defense","volume":"10","author":"Larochette V","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_8_46_1","article-title":"Topical treatments for chronic plaque psoriasis","volume":"3","author":"Mason AR","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013"},{"key":"e_1_2_8_48_1","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects","volume":"100","author":"Reid C","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10941.x"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12110"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_2_8_60_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/PTT.S179283","article-title":"Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential","volume":"9","author":"Chiricozzi A","year":"2019","journal-title":"Psoriasis Targets Ther"},{"issue":"9624","key":"e_1_2_8_61_1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin\u201012\/23 monoclonal antibody, in patients with psoriasis: 76\u2010week results from a randomised, double\u2010blind, placebo\u2010controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi CL","year":"2008","journal-title":"Lancet"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17628"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14867"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-008-9233-0"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08564.x"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10615.x"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08732.x"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17036"},{"issue":"12","key":"e_1_2_8_76_1","first-page":"1441","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb AB","year":"2014","journal-title":"J Drugs Dermatology"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.734"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21233"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16018"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.042"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12066"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.058"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.023"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"issue":"1","key":"e_1_2_8_88_1","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3899\/jrheum.140189","article-title":"Pregnancy outcomes in subjects exposed to certolizumab pegol","volume":"42","author":"Clowse MEB","year":"2015","journal-title":"J Rheumatol"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810652"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0265-y"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15666"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12235"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10257.x"},{"issue":"10","key":"e_1_2_8_98_1","first-page":"1002","article-title":"Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis","volume":"16","author":"Bissonnette R","year":"2017","journal-title":"J Drugs Dermatology"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.043"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.011"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501646"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1624"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15653"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1587145"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"e_1_2_8_116_1","unstructured":"ClinicalTrials.gov.A study to evaluate the efficacy and safety of bimekizumab compared to placebo and an active comparator in adult subjects with moderate to severe chronic plaque psoriasis (BE VIVID) [Internet]. [cited 2020 Apr 24]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03370133"},{"key":"e_1_2_8_117_1","unstructured":"ClinicalTrials.gov.A study to evaluate the efficacy and safety of bimekizumab compared to an active comparator in adult subjects with moderate to severe chronic plaque psoriasis (BE RADIANT) [Internet]. [cited 2020 Apr 24]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03536884"},{"key":"e_1_2_8_118_1","unstructured":"ClinicalTrials.gov.A study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (BE SURE) [Internet]. [cited 2020 Apr 24]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03412747"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.024"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2018.56"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.34"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.017"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12817"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.12.1366"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16102"},{"issue":"1210","key":"e_1_2_8_126_1","article-title":"Transcription factor retinoid\u2010related orphan receptor \u03b3t: a promising target for the treatment of psoriasis","volume":"9","author":"Tang L","year":"2018","journal-title":"Front Immunol"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.041"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsji.12946","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sji.12946","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/sji.12946","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sji.12946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T13:29:56Z","timestamp":1696426196000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sji.12946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":126,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1111\/sji.12946"],"URL":"https:\/\/doi.org\/10.1111\/sji.12946","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"value":"0300-9475","type":"print"},{"value":"1365-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"2020-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12946"}}